Recent Breakthrough Designations Break New Ground
This article was originally published in The Pink Sheet Daily
Vaccines and gene therapies are added to the list of types of drugs that could garner the expedited development pathway from the U.S. regulatory agency, with Novartis and Celladon being the most recent companies to tout the status.
You may also be interested in...
Pressure For Bexsero: Fate Of Novartis Vaccines Unit Hangs On Success
The EU CHMP’s recommendation in favor of Novartis’ Meningitis B vaccine Bexsero is a positive turn for the company’s vaccines business, but with the division’s sales and profits languishing, some investors are wondering if Novartis should cut its losses and get out of the space.
Celladon Hopes To Bring Gene-Therapy Solution To Heart Failure Patients
Improving heart contractility by increasing levels of the SERCA2a gene is a new approach to a familiar problem in treating heart failure.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.